Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LakeShore Biopharma ( (LSBCF) ) just unveiled an update.
On January 21 and 22, 2026, LakeShore Biopharma reported that arbitral awards issued by the Kaifeng Arbitration Commission require its affiliated entities, Liaoning Yisheng Biopharma and Beijing Yisheng Biotechnology, to pay counterparties a combined principal of roughly RMB504.5 million plus more than RMB72 million in interest and fees. The company disputes both the claims and the validity of the arbitration decisions, pledging to vigorously challenge the awards in the relevant tribunals; it also highlighted that, on December 12, 2024, the Shenyang Municipal Public Security Bureau opened a “fraudulent litigation” investigation into the underlying actions and that former chairman Yi Zhang, whom the company believes fabricated the cases, has been named a criminal suspect, underscoring significant legal uncertainty with potentially material financial and governance implications for stakeholders.
The most recent analyst rating on (LSBCF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSBCF Stock Forecast page.
Spark’s Take on LSBCF Stock
According to Spark, TipRanks’ AI Analyst, LSBCF is a Neutral.
LakeShore Biopharma’s overall stock score is primarily impacted by its financial performance, which shows strong gross profit margins but significant challenges with profitability and cash flow. Technical analysis indicates a bearish trend, and the lack of valuation data further contributes to a lower score. The absence of earnings call and corporate events data means these components do not influence the score.
To see Spark’s full report on LSBCF stock, click here.
More about LakeShore Biopharma
LakeShore Biopharma Co., Ltd is a China-based biopharmaceutical company headquartered in Beijing’s Daxing Biomedical Industry Park, focusing on the development and commercialization of biotech and pharmaceutical products for the healthcare market.
Average Trading Volume: 4,468
Technical Sentiment Signal: Sell
Current Market Cap: $35.03M
See more insights into LSBCF stock on TipRanks’ Stock Analysis page.